HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G nabs Nioxin

This article was originally published in The Rose Sheet

Executive Summary

With purchase of Nioxin Research Laboratories, announced Sept. 3, P&G gains range of innovative professional hair-care products that focus on the scalp to improve appearance of thinning hair, firm says. Nioxin offerings currently are distributed through salons and salon stores in more than 40 countries, P&G says. Acquisition is in harmony with P&G's strategy of focusing on "faster growing, higher margin and more asset-efficient businesses," according to release. The personal care giant will keep Nioxin's brand portfolio, organization and distribution network in place in order to strengthen its commitment to growth in professional salon channel; Brian Graham will stay on as CEO of Nioxin, P&G notes. "This acquisition is a great strategic fit given P&G's leadership and proven strength in its retail scalp care business. Further, P&G's global scale creates opportunities to further grow the Nioxin brand in key markets around the world," says Robert Jongstra, president, P&G Professional Care

You may also be interested in...



Pro Hair-Care Firm Nioxin Looks To Expand Global Reach As P&G Subsidiary

Procter & Gamble's acquisition of Nioxin positions the professional hair-care company to expand its reach globally and potentially become a "billion dollar brand," according to Nioxin CEO Brian Graham

NeuClone’s Trastuzumab Trial Succeeds

NeuClone has reported that its NeuCeptin proposed biosimilar trastuzumab has successfully met all primary and secondary endpoints in a Phase I clinical trial.

EMA Prepares Approval Verdict On Beovu, Idhifa, Recarbrio

Products from Novartis, Celgene and Merck could get an EU approval recommendation at this week's CHMP meeting.

UsernamePublicRestriction

Register

RS015650

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel